A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

201345 citationsJournal Articlegold Open Access

Authors

Ivana Filipović · AbbVie (United Kingdom)

Katherine Gooch · AbbVie (United States)

Abstract

Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources.

Topics & Keywords

Respiratory viral infections research Neonatal Respiratory Health Research Congenital Diaphragmatic Hernia Studies

Publication Details

Published in: Health Economics Review

Volume 3, Issue 1, pp. 18-18

DOI: 10.1186/2191-1991-3-18

Field-Weighted Citation Impact: 2.44

Command Palette

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

Authors

Abstract

Topics & Keywords

Publication Details